Glaucoma Following Surgery

2

Review clinical trials related to Glaucoma Following Surgery. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Long-Term Clinical Results of Ab-Interno Trabeculotomy in Glaucoma Management

Glaucoma is one of the leading causes of irreversible vision loss worldwide. Elevated intraocular pressure (IOP) is the most important risk factor for the development and progression of the disease. Ab-interno trabeculotomy (AIT) using the Trabectome system is a minimally invasive glaucoma surgery (MIGS) that reduces aqueous humor outflow resistance by ablating the trabecular meshwork and the inner wall of Schlemm's canal, thereby lowering intraocular pressure. Previous studies have demonstrated good short-term efficacy of this procedure. However, robust long-term data spanning several years remain scarce. The aim of this study is to evaluate the long-term outcomes of AIT in glaucoma patients who underwent surgery between 2019 and 2021 at the Department of Ophthalmology, University Hospital Würzburg. Patients are invited for a single study visit at which intraocular pressure, visual acuity, anterior chamber angle by gonioscopy, and optic nerve structure by optical coherence tomography (OCT) are assessed. The collected data are compared with pre-operative baseline values obtained from medical records. The results are intended to improve the assessment of long-term surgical success and to optimize patient selection for this procedure in the future.

Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Wuerzburg University HospitalUpdated: Aug 25, 2026Locations: 1
Eligibility criteria

Diagnosis of glaucoma [+4]

Inability to attend the study visit [+2]

Status: Recruiting

Topical Infliximab in Eyes With Penetrating Keratoplasty

Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.

Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Centre hospitalier de l'Université de Montréal (CHUM)Updated: Apr 27, 2026Locations: 1
Eligibility criteria

Age between 18 and 80 years; [+3]

Active ocular infection; [+10]